Evofem Biosciences Inc, (NASDAQ: EVFM), a commercial-stage biopharmaceutical company, has enrolled the first patient in its pivotal Phase three clinical trial assessing the safety and efficacy of EVO100 for the prevention of urogenital chlamydia and gonorrhoea in women, it was reported on Tuesday.
EVOGUARD is a double-blind, placebo-controlled Phase three clinical trial aimed at assessing the safety and efficacy of the product intended for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoea infection in women.
The study is to enrol 1,730 women who have had a urogenital chlamydia or gonorrhoea infection at any time over the 16 weeks preceding the enrolment visit, along with one or more risk factors for infection.
Alumis reports new Phase 3 data showing sustained skin clearance with envudeucitinib
FDA approves Genentech's Tecentriq combination therapy for stage III colon cancer
Sophos IRB and ALCMI partner to support lung cancer research
Innovent Biologics achieves primary study endpoint for inactive thyroid eye disease antibody
argenx reports positive Phase 2 results for FB102 in coeliac disease
Vir Biotechnology's VIR-5500 receives FDA Fast Track designation for prostate cancer
FDA accepts Bayer's application for KERENDIA in chronic kidney disease without diabetes
WuXi AppTec awarded EcoVadis gold medal for third year
Suzhou Ribo Life Science submits Phase I Clinical Trial Application for RBD3133 in EU
Roche Diagnostics supplies molecular testing instruments to support Ebola response in the DRC